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Abstract: Switching from immunotherapy to targeted therapy in metastasized melanoma can be compli-
cated by a cytokine release syndrome (CRS). CRS is a serious complication, which is induced by high
levels of circulating cytokines, associated with T-cell engagement and proliferation, and results in a con-
stellation of symptoms with variable organ involvement. We report 2 patients with BRAF V600 mutant
melanoma who were previously treated with anti-PD-1±anti-LAG-3 antibodies and were switched to
BRAF/MEK-inhibitors because of progressive disease. Both cases depict the complexity of interactions
occurring during sequential treatment with immune checkpoint inhibitors and kinase inhibitors. Early
identification and management of CRS is crucial to decrease its toxicity and improve safety of further
drugs to be given in a therapeutic ladder.
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